CB 4332 / Vertex - LARVOL DELTA

Model-based interspecies scaling for predicting human pharmacokinetics of CB 4332, a complement factor I protein. (PubMed, J Pharm Sci) - "The traditional dose-by-factor approach calculated a maximum recommended starting SC dose of 0.9 mg/kg once weekly, which was predicted it to result in a trough steady-state concentration lower than the determined efficacy target range for CB 4332 in humans. Model simulations predicted the efficacy target range to be reached using 5 mg/kg once weekly SC dosing."

Journal • PK/PD data